Sarepta Therapeutics, Inc. or Mesoblast Limited: Who Manages SG&A Costs Better?

Biotech Giants: SG&A Cost Management Showdown

__timestampMesoblast LimitedSarepta Therapeutics, Inc.
Wednesday, January 1, 20145417000049315000
Thursday, January 1, 20156537800075043000
Friday, January 1, 20165226300083749000
Sunday, January 1, 201735072000122682000
Monday, January 1, 201827415000207761000
Tuesday, January 1, 201936983000284812000
Wednesday, January 1, 202050918000317875000
Friday, January 1, 202163586000282660000
Saturday, January 1, 202257967000451421000
Sunday, January 1, 202353107000481871000
Monday, January 1, 202423626000
Loading chart...

Unlocking the unknown

SG&A Cost Management: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Sarepta Therapeutics, Inc. and Mesoblast Limited offer a fascinating study in contrasts. From 2014 to 2023, Sarepta's SG&A expenses surged by over 870%, peaking in 2023. This reflects their aggressive expansion and investment in R&D. In contrast, Mesoblast's SG&A costs fluctuated, peaking in 2015 and then declining by 64% by 2024, indicating a more conservative approach.

While Sarepta's strategy may suggest robust growth, it also raises questions about sustainability. Mesoblast, with its more stable SG&A trajectory, might appeal to investors seeking steadiness. The absence of 2024 data for Sarepta leaves room for speculation on their future cost management strategies. As these companies navigate the biotech landscape, their SG&A management will be pivotal in shaping their financial narratives.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025